EUCTR2016-000404-28-DK进行中（未招募）1 期
5, 6 or 7 year follow-up control after the SCHEDULE study (SCANDINAVIAN HEART TRANSPLANT EVEROLIMUS DE NOVO STUDY WITH EARLY CNI AVOIDANCE) (Protocol: CRAD001ANO02, EudraCT no.: 2009-013074-41)Title of the original SCHEDULE study:A controlled randomized open-label multicentre study evaluating if early initiation of everolimus (Certican®)and early elimination of cyclosporine (Sandimmun Neoral®) in de novo heart transplant recipients can improve long-term renal function and slow down the progression of chronic allograft vasculopathy. - 5, 6 or 7 year follow-up control after the SCHEDULE study
ovartis Norge AS0 个研究点目标入组 115 人开始时间: 2016年6月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 115
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients who participated in the SCHEDULE 12-month main study, and who completed the 3 year follow-up visit, and are coming for an annual clinic visit 5 or 7 years after randomization in the main study (Protocol: CRAD001ANO02, EudraCT no.: 2009-013074-41).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 18
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 7
排除标准
- •Patients who NOT participated in the SCHEDULE 12-month main study, and who NOT completed the 3 year follow-up visit (Protocol: CRAD001ANO02, EudraCT no.: 2009-013074-41).
研究者
相似试验
进行中（未招募）
1 期
5, 6 or 7 year follow-up control after receiving a new heart.Heart transplantationMedDRA version: 19.0Level: PTClassification code 10019314Term: Heart transplantSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2016-000404-28-SEovartis Norge AS115
已完成
4 期
SCHEDULE Follow Up Visit 5-7 yrHeart TransplantationNCT02864706Novartis Pharmaceuticals95
进行中（未招募）
1 期
ong-term follow-up of the patients enrolled in the SCHEDULE trial, in which we randomly allocated heart transplant recipients to standard treatment with the immunosuppressant ciclosporine or the newer imunosuppressant everolimus.Herat transplantMedDRA version: 21.1 Level: LLT Classification code 10050432 Term: Prophylaxis against heart transplant rejection System Organ Class: 100000004865EUCTR2019-004831-21-NOOslo University Hospital120
已完成
4 期
Six year follow up of children at high hereditary risk of allergy born to mothers participating in the DOMInO Trial.Atopy & Allergic DiseaseInflammatory and Immune System - AllergiesAlternative and Complementary Medicine - Other alternative and complementary medicineInflammatory and Immune System - Normal development and function of the immune systemACTRN12615000498594Women's & Children's Health Research Institute668
已完成
不适用
Further maintenance of remission for a year after Qing-Dai withdrawalin ulcerative colitis treatment:randomized controlled trialulcerative colitisJPRN-UMIN000028574Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University40